Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
about
Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and BeyondAutophagy and the (Pro)renin ReceptorRapamycin Promotes Mouse 4T1 Tumor Metastasis that Can Be Reversed by a Dendritic Cell-Based VaccineMoving Past Anti-VEGF: Novel Therapies for Treating Diabetic RetinopathymTOR: a potential therapeutic target in osteoarthritis?Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated ProteinsGemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways.Immune evasion strategies used by Helicobacter pylori.Anti-influenza neuraminidase inhibitor oseltamivir phosphate induces canine mammary cancer cell aggressiveness.Fasting regulates EGR1 and protects from glucose- and dexamethasone-dependent sensitization to chemotherapy.Serendipity in splendid isolation: rapamycinAnalysis of Proteins That Rapidly Change Upon Mechanistic/Mammalian Target of Rapamycin Complex 1 (mTORC1) Repression Identifies Parkinson Protein 7 (PARK7) as a Novel Protein Aberrantly Expressed in Tuberous Sclerosis Complex (TSC)P70S6 kinase phosphorylation: a new site to assess pharmacodynamy of sirolimus.Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatmentEcdysone Receptor-based Singular Gene Switches for Regulated Transgene Expression in Cells and Adult Rodent Tissues.The role of the chemokine receptor XCR1 in breast cancer cells.Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitationsCo-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment.Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies.Next-generation phenotypic screening.Human mesenchymal stem cells as a novel platform for simultaneous evaluation of cytotoxicity and genotoxicity of pharmaceuticals.Molecular signaling cascades involved in nonmelanoma skin carcinogenesis.Multi-targeted therapy of everolimus in Kaposi's sarcoma associated herpes virus infected primary effusion lymphoma.Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin.Multicomponent High-throughput Drug Screening via Inkjet Printing to Verify the Effect of Immunosuppressive Drugs on Immune T Lymphocytes.Everolimus-associated Acute Kidney Injury in Patients with Metastatic Breast Cancer.Natural small-molecule enhancers of autophagy induce autophagic cell death in apoptosis-defective cells.Targeting the master regulator mTOR: a new approach to prevent the neurological of consequences of parasitic infections?Hygromycin B hypersensitive (hhy) mutants implicate an intact trans-Golgi and late endosome interface in efficient Tor1 vacuolar localization and TORC1 function.Drug repurposing for the treatment of glioblastoma multiforme.
P2860
Q26751462-ECB4E2D7-2810-406E-A25B-7A73F55D03EAQ26849212-BE21BC7B-6D9A-4C65-A3DE-B1FDFB723EFDQ27317214-0126DB64-333E-431C-8365-48A38F2A9191Q28078199-65F164E6-D691-4017-A2F3-4F0428DD9665Q28087019-CC241052-7475-4BCA-A0C8-89FC6B6BCC46Q28552225-3EEF42FF-384E-4729-B3C8-E2A4AB8EEA03Q33779061-50C32F02-D26A-4F7F-873C-322F37F64D8BQ34255412-063430C2-7AF6-4DDA-8BE8-07B50C97D427Q35303234-A70CA473-4548-4989-82F7-A4A06164E988Q36328064-89C81F6E-15BA-4174-8A53-2E169FE69A21Q36443126-E3DB2EC7-97E5-4AEC-BAC0-B91CB03206FFQ36539459-1E010FFD-4125-4D4E-A161-608D323BDEEDQ36807172-BEEF69B0-732D-4009-BF90-5B3C30DE2129Q36997524-34330E51-4774-4B5E-B151-FE37523E6265Q37325093-461069D3-6FBA-4D12-A126-94969D97A56AQ37742024-371E3171-32DD-4982-96A4-92EA2860163AQ38208069-B07800B0-6FA2-40DE-AC17-6D1FFCC85ED3Q38741022-AF7BC5E1-D67F-4FDB-91E8-CC210AA1D97AQ38815881-DE8AC95B-E1FB-498A-8B13-4B057BA2BFD7Q38846991-16E149B0-9B0C-4BA8-9132-8EF13700463FQ38924069-3C507CFE-B35D-46D3-9C28-13052F45E30CQ38966698-43533BD8-9485-436D-B005-8BD0AB916F3BQ40144368-9E3DE01F-0F51-4FDE-AA36-D19019A87ADBQ40970978-E3278D19-2C69-4ED1-97BD-99FAF9943967Q41109573-32BDDC0F-9F88-4513-8EFB-CBC549248FA5Q41513847-60406D73-05E0-4B4E-B650-7F1A445EA540Q41552829-5CBF5755-913D-47AC-9E2A-4E64CCC4CB3CQ45840900-12A59F5D-3856-44AB-AE86-9D2F78A4C07BQ46455388-2615794E-11CA-4014-AE97-0553EFE16811Q47948290-D4C09834-2551-4457-AD6D-1F6A48140C4E
P2860
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
@ast
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
@en
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
@nl
type
label
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
@ast
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
@en
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
@nl
prefLabel
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
@ast
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
@en
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
@nl
P2860
P356
P1476
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
@en
P2093
Belinda Seto
P2860
P2888
P356
10.1186/2001-1326-1-29
P577
2012-11-15T00:00:00Z
P5875
P6179
1050375921